David Meeker starts a new biotech chapter in his career; Sam Kulkarni takes the helm at CRISPR
→ David Meeker left Genzyme last April after a 23-year run, including six years as president after Sanofi stepped in to buy the landmark biotech six years ago. Five months later, after adding a string of biotech board positions to his schedule, Meeker has landed his next big gig in biotech running KSQ Therapeutics in Cambridge, MA. At KSQ, he says, you can start an experiment using cutting edge technology and no bias about outcomes. With CRISPR,“we can study all 20,000 genes in the genome across a multitude of disease models and find out which of those targets has the biggest impact in modulating the disease. We can do it one shot, 20,000 genes at a time.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
